Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9589231 | 0.89 | HTT (0.47) | MEN1TP53KMT2ASMN1; SMN2HTT | |
| SCHEMBL9402303 | 0.84 | KDM4E (0.41) | MEN1TP53KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL9767502 | 0.81 | ALDH1A1 (0.52) | MEN1TP53KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL9402239 | 0.77 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL9402332 | 0.77 | CYP3A4 (0.60) | MEN1TP53KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL9402280 | 0.76 | KDM4E (0.70) | MEN1KMT2AKDM4ESMN1; SMN2HTT | |
| SCHEMBL9402219 | 0.71 | — | — | |
| SCHEMBL9402246 | 0.70 | ALDH1A1 (0.51) | KMT2AHTTALDH1A1MAPT | |
| SCHEMBL5655480 | 0.70 | ALDH1A1 (0.35) | MEN1TP53KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL9402365 | 0.67 | TLR7 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5045540-A | Amide or urea compounds containing imidazole groups | WARNER-LAMBERT CO. (US) | 1991-09-03 | — | — | US | disclosed |
| US-5041552-A | Treatment of hypertension, heart failure, glaucoma and hyperaldosteronism | WARNER-LAMBERT COMPANY (US) | 1991-08-20 | — | — | US | disclosed |